The MASH treatment landscape is evolving rapidly, driven by a diverse array of therapeutic classes, each with unique mechanisms and potential impacts. The forecast period reveals significant shifts and emerging trends that will shape future […]
Tag: DelveInsight Business Research
How In-Licensing Led to the Selection of a High-Value Game-Changing Asset for a Pharma Client
A case study on how a mid-sized pharmaceutical company collaborated with DelveInsight to expand its asset portfolio in the Atrial Fibrillation space. DelveInsight conducted comprehensive asset prioritization, identifying the most promising Phase II therapeutic candidates […]
Chronic Heart Failure Market to Observe Stunning Growth at a CAGR of 10% by 2034 Owing to Strong Uptake of Entresto and approved SGLT2 Inhibitors along with Emergence of New Class of Therapies
Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus […]
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment
The high and growing incidence of tuberculosis (TB) cases globally, especially in high-burden countries, is a major driver for both the treatment drugs and diagnostics markets. TB remains a significant public health challenge, with millions […]
Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making
A case study on how a leading pharma company in hematology turned to DelveInsight for long-term competitive intelligence support. DelveInsight provided an in-depth analysis of competitive activity in key hematological malignancies, helping the company stay […]
